ABT vs ALL Stock Comparison

Scores Breakdown

Metric	ABT	ALL
📈 Growth	22/30	22/30
💰 Profitability	17/20	14/20
🏦 Financial Health	15/20	18/20
💵 Valuation	12/20	10/20
⚠️ Risk (lower is better)	4/10	6/10
Overall Score	72/100	68/100

Side-by-Side Summaries

ABT Analysis	ALL Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Across 8 quarters, Allstate’s revenue rose from about $15.714B (2024-Q2) to about $16.941B (2026-Q1), up roughly 7.8%. Net income climbed from about $0.347B to $2.458B, a multi‑fold increase, with a notable surge in late‑2025 before a softer start in 2026. The trend is positive overall but shows quarterly volatility (e.g., 2025‑Q1 dip followed by stronger 2025‑Q3/Q4). End‑period profitability remains sensitive to cost structure and mix, yet margins improved from multi‑quarter lows to mid‑teens late in 2025 and into 2026. 💰 Margins & Cash Flow Operating margin ranged from about 2.7% (2024‑Q2) to about 28.4% (2025‑Q4), with several quarters in the mid‑teens, indicating substantial margin volatility but a capability to leverage scale when costs align with revenues. Net cash flow from operating activities remained positive in all quarters, averaging around $3.0B per quarter; notably, 2026‑Q1 shows operating cash flow near $3.56B. Investing cash flow was often negative, reflecting capital allocation and reserve considerations, while financing activity flow fluctuated, contributing to variances in overall cash balance. 🛡️ Balance Sheet & Liquidity Current assets consistently exceed current liabilities, yielding a healthy current ratio around 1.3x (roughly 1.29–1.34 over periods). Long‑term debt sits near $8.08B with total liabilities largely dominated by insurance reserves and operating liabilities, while equity (≈$21–31B across periods) provides a meaningful buffer; periods show equity around $24–31B and liabilities near $92–93B. ⚠️ Key Drivers & Risks Drivers: prudent pricing and reserving practices within P&C insurance; managing catastrophe exposure and capital allocation. Risks: quarterly earnings are sensitive to claim volatility and reserve adequacy; macro factors and regulatory changes can impact pricing and claims experience, affecting valuation sensitivity and downside scenarios.

ABT Analysis

ALL Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Across 8 quarters, Allstate’s revenue rose from about $15.714B (2024-Q2) to about $16.941B (2026-Q1), up roughly 7.8%. Net income climbed from about $0.347B to $2.458B, a multi‑fold increase, with a notable surge in late‑2025 before a softer start in 2026.

The trend is positive overall but shows quarterly volatility (e.g., 2025‑Q1 dip followed by stronger 2025‑Q3/Q4). End‑period profitability remains sensitive to cost structure and mix, yet margins improved from multi‑quarter lows to mid‑teens late in 2025 and into 2026.

💰 Margins & Cash Flow

Operating margin ranged from about 2.7% (2024‑Q2) to about 28.4% (2025‑Q4), with several quarters in the mid‑teens, indicating substantial margin volatility but a capability to leverage scale when costs align with revenues.
Net cash flow from operating activities remained positive in all quarters, averaging around $3.0B per quarter; notably, 2026‑Q1 shows operating cash flow near $3.56B.
Investing cash flow was often negative, reflecting capital allocation and reserve considerations, while financing activity flow fluctuated, contributing to variances in overall cash balance.

🛡️ Balance Sheet & Liquidity

Current assets consistently exceed current liabilities, yielding a healthy current ratio around 1.3x (roughly 1.29–1.34 over periods).
Long‑term debt sits near $8.08B with total liabilities largely dominated by insurance reserves and operating liabilities, while equity (≈$21–31B across periods) provides a meaningful buffer; periods show equity around $24–31B and liabilities near $92–93B.

⚠️ Key Drivers & Risks

Drivers: prudent pricing and reserving practices within P&C insurance; managing catastrophe exposure and capital allocation.
Risks: quarterly earnings are sensitive to claim volatility and reserve adequacy; macro factors and regulatory changes can impact pricing and claims experience, affecting valuation sensitivity and downside scenarios.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"